Insider Brief
- Nuritas raised $42 million in an oversubscribed Series C funding round led by M&G Investments and McWin Capital Partners, with participation from Grosvenor and ECBF, to scale operations and expand its AI-driven peptide ingredient innovation.
- The company’s Magnifier™ AI platform accelerates peptide discovery for health-focused products, achieving a clinical success rate over 80%, with flagship products like PeptiStrong™ for muscle repair and PeptiYouth™ for skin rejuvenation already integrated into global consumer products.
- Strategic partnerships with Nestlé, Mars, and others, along with the funding, will support the development of new peptides and global growth, advancing Nuritas’ mission to create sustainable, health-driven solutions.
PRESS RELEASE — Nuritas, a trailblazer in AI-powered peptide discovery, has successfully closed an oversubscribed $42 million Series C funding round. This funding marks a pivotal moment in Nuritas’ mission to improve the lives of billions by redefining the future of health and nutrition through groundbreaking ingredient innovation. The round was led by M&G Investments, on behalf of its Catalyst strategy — a purpose-led initiative supporting transformative businesses addressing global social and environmental challenges. McWin Capital Partners, a private equity and venture capital firm focused on high-growth companies in the food ecosystem, also joined as a key investor, further solidifying Nuritas’ foundation for global expansion. Current investors Grosvenor and ECBF also participated in the round.
Revolutionizing Ingredient Innovation
Most ingredients available today fail to meet the health and wellness demands of modern consumers. This is demonstrated by the huge health crisis we are experiencing globally. Developing new health-focused ingredients is slow and a costly process taking decades and costing 10s to 100s of millions. Rooted in years of deep science Nuritas is changing the paradigm of ingredients discovery by bringing to market previously inaccessible health promoting peptide ingredients discovered in various food plant sources.
“Our mission is to improve the lives of billions by creating ingredients that address pressing global health challenges,” said Dr. Nora Khaldi, Founder and CEO of Nuritas. “Through our science-first approach, we are fundamentally shifting the paradigm of ingredient discovery, enabling our customers to deliver healthier, differentiated products that meet the needs of today’s consumers.”
A Deep Commitment to Science and Customer-Centric Solutions Driving Market Impact
With nearly a decade of groundbreaking research, Nuritas has built the world’s largest peptide knowledge base. Its cutting-edge AI platform Magnifier™ identifies peptides 10–50 times faster than traditional methods, with an industry-leading clinical success rate of over 80%, far exceeding industry standards of low single digits. As demonstrated by the numerous impactful customer product launches with Nuritas ingredients, Nuritas’ scientifically validated ingredients empower its partners to:
• Increase market penetration and differentiation with innovative, evidence-based products.
• Truly address end-consumer needs with solutions validated through rigorous science and clinical trials.
PeptiStrong™, Nuritas’ patented flagship peptide derived from fava beans, supports muscle generation and repair, has achieved FDA-approved GRAS (Generally Recognized as Safe) status in the U.S. and is already integrated into consumer products across multiple continents. It has been validated by three human clinical trials, demonstrating benefits like improved strength, faster recovery, and sustained energy.
Additionally, Nuritas recently launched PeptiYouth™, a peptide that reduces wrinkle depth by promoting collagen production. This breakthrough ingredient, discovered after millions of years of being hidden in nature, is now featured in skin-care products in the U.S. and Asia. Nuritas plans to introduce three new clinically validated peptide ingredients in 2025, further expanding its innovative portfolio.
Strategic Partnerships and Industry Recognition
Nuritas’ revolutionary peptides have attracted high-profile partnerships with leading global companies, including Givaudan, Nestlé, Mars, and Sumitomo Corporation. These collaborations highlight the broad applications of Nuritas’ bioactive peptides across functional foods, dietary supplements, medical foods, cosmetics, and food technology.
Scaling for Global Growth
The $42 million funding will enable Nuritas to scale its operations, expand its global customer base, and reach more consumers worldwide. With products spanning pharmacies, retail outlets, online platforms, and specialty stores, Nuritas is poised to drive the next generation of health-focused, sustainable ingredients.
“We are thrilled to welcome M&G’s Catalyst team and McWin Capital Partners, who share our vision of making healthier ingredients accessible to billions of people globally,” added Dr. Khaldi. “This investment, alongside the addition of experienced board members, will propel our mission to new heights.”
New Board Members to Guide Expansion
As part of the funding round, Nuritas welcomes Alex Seddon, Head of Impact & Private Equity at M&G Investments, and Henry McGovern, co-founder of McWin Capital Partners, to its Board of Directors. Both bring extensive expertise in scaling high-growth companies and are committed to advancing Nuritas’ vision.
Alex Seddon commented: “ We are proud to lead this round of investment into Nuritas, as they continue to leverage the AI-powered Magnifier platform to discover novel, functional ingredients that will provide broad-based preventative health benefits. This investment reflects our commitment to supporting scalable solutions that deliver measurable impact. By partnering with Nuritas, we look forward to supporting their groundbreaking work, ultimately advancing sustainable, healthier outcomes for people and the planet.”
Martin Davalos, Partner & Head of Food Tech at McWin Capital Partners added: “We are thrilled to join Nuritas at this pivotal moment in their journey. Henry McGovern and I bring complementary expertise, and together with the Nuritas team, we are excited to help accelerate their growth. We are passionate about healthier, safer and more sustainable products and believe consumers worldwide should have the right to access these with ease — and Nuritas are at the forefront of developing technology and products to meet that need.”
About Nuritas:
Nuritas is a B2B leader in scientifically backed peptide ingredients for health and nutrition Through its groundbreaking AI-powered proprietary Magnifier™ platform, Nuritas identifies peptides with unique properties, enabling its customers to create differentiated products that address today’s consumer needs. With a mission to improve the lives of billions, Nuritas is setting the standard for the future of ingredient innovation.
About M&G’s Catalyst Strategy M&G’s Catalyst strategy provides capital to purpose-driven businesses addressing critical global challenges while seeking long-term financial returns. The strategy manages investments on behalf of M&G’s £126 billion With Profits Fund, which includes PruFund.
About McWin Capital McWin Capital Partners is a specialist private equity and venture capital firm focused on the food ecosystem. Dedicated to fostering innovation, McWin supports high-growth companies that drive positive social impact and scalability.
For media inquiries:
Nuritas Communications Team
Email: [email protected]
Phone: +353–1–234–5678
Website: www.nuritas.com
